Search This Blog

Monday, June 23, 2025

Revolution Medicines Breakthrough Tag for Daraxonrasib in Metastatic Pancreatic Cancer

 

  • Breakthrough Therapy Designation based on promising early clinical evidence observed with daraxonrasib in patients with pancreatic ductal adenocarcinoma (PDAC)

  • RASolute 302, a Phase 3 registrational study of daraxonrasib in patients with previously treated metastatic PDAC, expected to substantially complete enrollment this year

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.